CAPEX.com
CAPEX.com

Article Hero

Johnson & Johnson plans to split

1636726465.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
12 November 2021
Healthcare giant Johnson & Johnson to split into two companies

The world's largest health-products company by sales revealed earlier today that it plans to split the consumer health division from the pharmaceuticals unit. After the split, the consumer health business will become a new publicly traded company.

Joaquin Duato,  J&J's CEO starting January 2022, stated: "The new Johnson & Johnson and the New Consumer Health Company would each be able to more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value."

Despite the split, the company plans to keep its total dividend "at least at the same level" – 2.6%.

The business separation is expected to be complete in 18 to 24 months. J&J will keep the pharmaceuticals and medical device units, expected to generate roughly $77 billion in revenue in 2021.

J&J is the second US company this week that announces a split, after General Electric. After the news hit the wires, Johnson & Johnson stock price added 4% before the opening bell.

Sources: reuters.com, wsj.com

This information prepared by capex.com/za is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of capex.com/zaJME Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.

Share this article

How did you find this article?

Awful
Ok
Great
Awesome

Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.